Prescriber information for the Exablate Model 4000 Neuro/Prime MRI-guided focused ultrasound system, publication PUB41002923, Revision 14, July 2025. Describes the device, indications for essential tremor and Parkinson’s disease, patient selection, contraindications, warnings, precautions, and potential adverse reactions. Includes clinical study evidence for essential tremor, the 1.5T head coil, and long-term follow-up. The contents also list studies of tremor-dominant Parkinson’s disease, pallidotomy, and staged contralateral treatments, whose full text is not included in the supplied excerpt.
Free preview text
The first 5 pages, shown as text so search engines and readers can find this document.
Page 1
PUB41002923, Rev 14
July 2025
EXABLATE MODEL 4000
TYPE 1.0 & TYPE 1.1
APPLICATION: BRAIN INDEX / STAGED CONTRALATERAL UNILATERAL
ESSENTIAL TREMOR, TREMOR DOMINANT PARKINSON’S DISEASE, &
PALLIDOTOMY MOTOR COMPLICATIONS PARKINSON’S DISEASE
INFORMATION FOR PRESCRIBERS
Page 2
INFORMATION FOR PRESCRIBERS
PUB41002923, Rev 14
CHAPTER # CHAPTER NAME
Chapter 1 OVERVIEW AND LABELING
Chapter 2 PATIENT SELECTION CRITERIA FOR TREATMENT WITH EXABLATE NEURO
Chapter 3 SUMMARY OF PIVOTAL CLINICAL STUDY
Chapter 4 CLINICAL STUDY – EXABLATE 1.5T HEAD COIL “PMA P150038/S002”
Chapter 5 LONG TERM CLINICAL DATA – ESSENTIAL TREMOR 5 YEARS DATA
Chapter 6 CLINICAL STUDY – TREMOR DOMINANT PARKINSON’S DISEASE “PMA P150038/S006”
Chapter 7 CLINICIAL STUDY - PALLIDOTOMY MOTOR COMPLICATIONS PARKINSON’S DISEASE
Chapter 8 CLINICAL STUDY – STAGED, CONTRALATERAL UNILATERAL THALAMOTOMY FOR ESSENTIAL
TREMOR
Chapter 9 CLINICAL STUDY DATA – CONTINUED ACCESS STUDY FOR ESSENTIAL TREMOR WITH 5-YEAR
FOLLOW-UP DATA
Chapter 10 CLINICAL STUDY DATA - STAGED, INDEX & CONTRALATERAL UNILATERAL PALLIDO-THALAMIC
MOTOR COMPLICATIONS PARKINSON’S DISEASE
Revision: 07/2025
Page 3
INFORMATION FOR PRESCRIBERS
PUB41002923, Rev 14
TABLE OF CONTENTS
CHAPTER 1: OVERVIEW AND LABELING ....................................................................................................................... 9
1.1 Device Description ...................................................................................................................................... 9
1.2 Intended Use / Indications for Use ............................................................................................................. 9
CHAPTER 2: PATIENT SELECTION CRITERIA FOR TREATMENT WITH EXABLATE NEURO ............................................ 11
2.1 Patient Selection Criteria .......................................................................................................................... 11
Essential Tremor.............................................................................................................................................. 11
(unilateral thalamotomy) ................................................................................................................................ 11
Essential Tremor for Bilateral Arm .................................................................................................................. 11
(bilateral thalamotomy) .................................................................................................................................. 11
Motor Complication Parkinson’s Disease ....................................................................................................... 11
(unilateral GPi pallidotomy, pallido-thalamic tractotomy) ............................................................................. 11
Tremor Dominant Parkinson’s ........................................................................................................................ 11
Disease ............................................................................................................................................................ 11
Motor Complication Parkinson’s Disease for Bilateral Side ............................................................................ 11
(bilateral pallido-thalamic tractotomy) ........................................................................................................... 11
2.2 Contraindications ...................................................................................................................................... 12
2.3 Warnings ................................................................................................................................................... 12
2.4 Precautions................................................................................................................................................ 14
2.5 Potential Adverse Reactions ..................................................................................................................... 14
CHAPTER 3: SUMMARY OF PIVOTAL CLINICAL STUDY – Essential Tremor ................................................................ 16
3.1 Study Design .............................................................................................................................................. 16
3.1.1 Eligibility Criteria............................................................................................................................... 16
3.1.1.1 Inclusion Criteria ................................................................................................................................. 16
3.1.1.2 Exclusion criteria ................................................................................................................................. 17
3.1.2 Patient Treatment ............................................................................................................................ 19
3.1.3 Study Follow Up ................................................................................................................................ 19
3.1.4 Study Endpoints ................................................................................................................................ 21
3.1.5 Study Statistical Analysis Plan and Analysis Population ................................................................... 22
3.1.5.1 Study Sample Size ............................................................................................................................... 22
3.1.5.2 Study Analysis Population ................................................................................................................... 23
3.1.6 Study Subject Accountability ............................................................................................................ 23
3.1.7 Study Demographics and Baseline Characteristics........................................................................... 26
3.2 Study Results ................................................................................................................................................ 27
3.2.1 Safety Results ................................................................................................................................... 27
3.2.1.1 Mental Status Assessment - PHQ-9..................................................................................................... 38
Page 4
INFORMATION FOR PRESCRIBERS
PUB41002923, Rev 14
3.2.2 Effectiveness Results ........................................................................................................................ 38
3.2.2.1 Primary Endpoint ................................................................................................................................ 38
3.2.2.2. Confirmatory Secondary Endpoints Safety Results ............................................................................ 39
3.2.2.2.1. PE Calculation (Composite Tremor/Motor Function Score) as Compared to Exablate Baseline
through Month 12 ........................................................................................................................................... 39
3.2.2.2.2 CRST Part C Total Score .................................................................................................................... 44
3.2.2.2.3 QUEST (Summary of Dimension Score) Baseline to Month 3 – Comparison between Groups – Main
Analysis – ITT Population ................................................................................................................................ 49
3.2.2.2.4 Summary of Main Efficacy................................................................................................................ 49
3.2.2.2.5 Covariate and Sensitivity Analyses ................................................................................................... 51
3.2.2.2.6 Additional Analyses – CRST Part – B................................................................................................. 52
3.2.2.3 Confirmatory Secondary Endpoints Safety Results ............................................................................. 52
3.2.2.3.1 Subject Disposition & Accountability ............................................................................................... 52
3.2.2.3.2 Subject Disposition & Accountability ............................................................................................... 53
3.2.2.3.3. Primary Efficacy Endpoint Subject Disposition & Accountability.................................................... 59
3.2.2.3.4. Crossover Analysis Confirmatory Endpoint—CRST Composite Tremor/Motor Function Score
Compared to Baseline. .................................................................................................................................... 60
3.2.2.3.5. CRST, Part A Posture Component ................................................................................................... 64
3.2.2.3.6. CRST Overall Part C Comparison to Baseline .................................................................................. 66
3.2.2.3.7. QUEST Endpoint Analyses compared to Baseline ........................................................................... 67
3.2.2.3.8. Additional Analyses – CRST Part-B Total Score ............................................................................... 68
3.3 Conclusions Drawn from the Studies ........................................................................................................... 69
3.3.1 Study Safety Conclusions .................................................................................................................. 69
3.3.2 Study Efficacy Conclusions ............................................................................................................... 70
3.3.3 Study Overall Conclusions ................................................................................................................ 71
CHAPTER 4: CLINICAL STUDY EXABLATE 1.5T HEAD COIL “PMA P150038/S02” ........................................................ 72
4.1 Investigational Objectives ......................................................................................................................... 72
4.2 Study Design ................................................................................................................................................. 72
4.2.1 Clinical Report Sample Size .................................................................................................................... 72
4.2.2 Selection of Study Population .......................................................................................................... 73
4.2.2.1 Inclusion criteria .................................................................................................................................. 73
4.2.2.2 Exclusion Criteria ................................................................................................................................. 73
4.2.3 Study Conduct .................................................................................................................................. 76
4.2.4 Pre-Treatment Data Collection and Procedures .............................................................................. 76
4.2.5 Study Treatment ............................................................................................................................... 76
4.2.6 Study Follow-up ................................................................................................................................ 76
4.3 Study Endpoints ........................................................................................................................................ 77
4.4 Results .......................................................................................................................................................... 77
Page 5
INFORMATION FOR PRESCRIBERS
PUB41002923, Rev 14
4.4.1 Demographics ................................................................................................................................... 77
4.4.2 CRST (Part A + Part B) Normalized Tremor Motor Function ............................................................ 78
4.4.3 CRST (Part A + Part B) Actual Value Tremor / Motor Function ........................................................ 79
4.4.4 Percent Tremor / Motor Function .................................................................................................... 81
4.4.5 CRST Part A Posture Upper Extremity Only ...................................................................................... 82
4.4.6 CRST Part C Total Score .................................................................................................................... 84
4.4.7 QUEST – Quality of Life ..................................................................................................................... 86
4.4.8 Summary of Results .......................................................................................................................... 87
4.4.9 Safety Assessment ............................................................................................................................ 88
4.5 Discussion and Overall Conclusion ............................................................................................................ 97
CHAPTER 5: SUMMARY OF long term follow-up CLINICAL STUDY – 5 years follow-up ............................................. 98
5.1. Study Purpose and Design............................................................................................................................... 98
5.1.1. Objectives .................................................................................................................................................. 98
5.1.2. Subject Population, Eligibility Criteria........................................................................................................ 98
5.1.3. Study Follow Up .................................................................................................................................. 100
5.1.4 Study Endpoints .............................................................................................................................. 101
5.1.4.1 Safety Endpoint ................................................................................................................................. 101
5.1.4.2 Effectiveness Endpoint ...................................................................................................................... 101
5.1.5 Analysis Population ........................................................................................................................ 101
5.1.5.1 Study Sample Size ............................................................................................................................. 101
5.1.5.2 Study Analysis Population ................................................................................................................. 101
5.1.6 Study Subject Accountability .......................................................................................................... 102
5.2 Study Results ........................................................................................................................................... 104
5.2.1 Safety Results ................................................................................................................................. 104
5.2.2 Effectiveness Results ...................................................................................................................... 109
5.3 Conclusions Drawn from The Study ........................................................................................................... 116
CHAPTER 6: SUMMARY OF CLINICAL STUDY – Tremor dominant parkinson’s disease ........................................... 117
6.1. Study Design .............................................................................................................................................. 117
6.1.1 Eligibility Criteria............................................................................................................................. 117
6.1.1.1 Inclusion Criteria ............................................................................................................................... 117
6.1.1.2 Exclusion criteria ............................................................................................................................... 119
6.1.4 Study Endpoints .............................................................................................................................. 122
6.1.5 Study Analysis Population .............................................................................................................. 123
6.1.6. Study Subject Accountability............................................................................................................... 124
6.1.7. Study Demographics and Baseline Characteristics ............................................................................. 127
6.2. Study Results ............................................................................................................................................. 128
6.2.1. Safety Results ...................................................................................................................................... 128
6.3 Efficacy Analysis ...................................................................................................................................... 140
Exablate Model 4000, Type 1.0 & Type 1.1 - Information for Prescribers: summary, contents and background
This guide helps you understand the scope of Exablate Model 4000, Type 1.0 & Type 1.1 - Information for Prescribers before or alongside reading the original document. It is based on the catalogue record, credited creator, source, classification and topics shown on this page. It does not replace the original work and does not invent claims about passages that Doxxly cannot verify.
Summary and overview
Exablate Model 4000, Type 1.0 & Type 1.1 - Information for Prescribers is a 379-page documentcredited to Petra X. Bellweather. Prescriber information for the Exablate Model 4000 Neuro/Prime MRI-guided focused ultrasound system, publication PUB41002923, Revision 14, July 2025. Describes the device, indications for essential tremor and Parkinson’s disease, patient selection, contraindications, warnings, precautions, and potential adverse reactions. Includes clinical study evidence for essential tremor, the 1.5T head coil, and long-term follow-up. The contents also list studies of tremor-dominant Parkinson’s disease, pallidotomy, and staged contralateral treatments, whose full text is not included in the supplied excerpt. It appears in the Medicine & Wellbeing collection, which groups it with other material that readers may use for comparison and further study.
The item can be approached in several ways. A reader looking for a quick orientation can begin with the free five-page preview, inspect the page structure and use the metadata to judge relevance. Someone undertaking deeper research can work through the complete file, search its indexed text, record useful page references and compare its treatment of Prescriber information, Exablate Model 4000, Exablate Neuro, MR-guided focused ultrasound, Essential tremor, Parkinson’s disease, Thalamotomy, Pallidotomy, Pallidothalamic tractotomy, Clinical studies, Device safety with the related resources linked below.
Rather than reducing the work to a single claim, this page treats it as a source that should be read in context. The title, creator, publication source, licence and format all help explain what kind of evidence it may offer. Readers should distinguish the original author's statements from Doxxly's catalogue description, and should cite the original edition when using the material in academic, professional or published work.
Key topics and reader takeaways
The catalogue connects this document with Prescriber information, Exablate Model 4000, Exablate Neuro, MR-guided focused ultrasound, Essential tremor, Parkinson’s disease, Thalamotomy, Pallidotomy, Pallidothalamic tractotomy, Clinical studies, Device safety. These terms offer practical entry points rather than a substitute for close reading. Start by identifying the definitions, examples, arguments, tables or visual explanations attached to each topic. Then note where the creator draws connections, makes distinctions or moves from background material to a conclusion, recommendation, calculation or narrative development.
A useful reading method is to separate description from interpretation. First record what the item actually presents: names, headings, figures, formulas, quotations or stated propositions. Next consider why those details matter within the whole work. Finally compare them with another source from the same subject area. This process helps turn a long digital file into evidence that can be evaluated rather than merely skimmed.
Table of contents and reading guide
The following is an editorial content guide based on the verified catalogue topics. It is not represented as the original author's formal table of contents. Use it to organise notes while moving through the 379 pages in the player.
Part 1
Prescriber information
Use this section of the reading guide to identify how Prescriber information appears in Exablate Model 4000, Type 1.0 & Type 1.1 - Information for Prescribers, note important terms, and connect the subject to the wider purpose of the work.
Part 2
Exablate Model 4000
Use this section of the reading guide to identify how Exablate Model 4000 appears in Exablate Model 4000, Type 1.0 & Type 1.1 - Information for Prescribers, note important terms, and connect the subject to the wider purpose of the work.
Part 3
Exablate Neuro
Use this section of the reading guide to identify how Exablate Neuro appears in Exablate Model 4000, Type 1.0 & Type 1.1 - Information for Prescribers, note important terms, and connect the subject to the wider purpose of the work.
Part 4
MR-guided focused ultrasound
Use this section of the reading guide to identify how MR-guided focused ultrasound appears in Exablate Model 4000, Type 1.0 & Type 1.1 - Information for Prescribers, note important terms, and connect the subject to the wider purpose of the work.
Part 5
Essential tremor
Use this section of the reading guide to identify how Essential tremor appears in Exablate Model 4000, Type 1.0 & Type 1.1 - Information for Prescribers, note important terms, and connect the subject to the wider purpose of the work.
Part 6
Parkinson’s disease
Use this section of the reading guide to identify how Parkinson’s disease appears in Exablate Model 4000, Type 1.0 & Type 1.1 - Information for Prescribers, note important terms, and connect the subject to the wider purpose of the work.
Part 7
Thalamotomy
Use this section of the reading guide to identify how Thalamotomy appears in Exablate Model 4000, Type 1.0 & Type 1.1 - Information for Prescribers, note important terms, and connect the subject to the wider purpose of the work.
Part 8
Pallidotomy
Use this section of the reading guide to identify how Pallidotomy appears in Exablate Model 4000, Type 1.0 & Type 1.1 - Information for Prescribers, note important terms, and connect the subject to the wider purpose of the work.
When a heading in the original differs from this guide, follow the original heading in your citation. Page numbers can also vary between editions. Doxxly's direct page field is useful for navigation, but formal references should include the title, creator, source and edition details available in the file itself.
About Petra X. Bellweather
Doxxly credits Petra X. Bellweather as the author or creator of Exablate Model 4000, Type 1.0 & Type 1.1 - Information for Prescribers. This page does not add an unverified biography, job title or institutional affiliation. The attribution is preserved so readers can distinguish the creator from the hosting library and follow the original record when an external author link is available.
Author context matters because a work reflects a particular purpose, audience and point of view. Before relying on the material, consider what the creator set out to explain, when the source was produced and whether later research or revised guidance should also be consulted. For literature and philosophy, compare translations and editions; for technical material, check whether a newer version has superseded the one shown here.
About the source organisation
The recorded source for this item is insightec.com. Doxxly provides access and discovery tools but does not claim to be the original publisher unless explicitly stated. Source links, creator attribution and the recorded Publicly available file collected for editorial review licence are displayed to help readers assess provenance and permitted use.
Provenance is especially important for reports, standards, presentations and working spreadsheets. Check the original source for amendments, supporting files and current policy. A trustworthy research workflow keeps the source URL with any notes or downloaded copy, verifies important figures against the original, and avoids treating an archived document as automatically current.
Begin with the title and opening pages, then use the guide above to decide whether to read sequentially or move to a particular topic. The Doxxly player provides previous and next navigation, a direct page field, zoom steps, fit-to-width and fit-to-page modes, rotation and fullscreen. These controls are useful when a page contains small type, a wide table, an image, a scanned layout or a dense sequence of notes.
The first five pages are open to every visitor. A plan unlocks the complete item and full-document search. Search is best used for distinctive names, technical terms or short phrases; broad words can produce too many possible contexts. When you find a useful passage, read the surrounding pages so that a sentence, chart or formula is not separated from its explanation.
If downloading is enabled, members can obtain the original PDF file. Keep the original format when formulas, slide sequencing, pagination or layout carries meaning. Respect the Publicly available file collected for editorial review terms displayed on this page, and use the rights-report link if you believe the attribution or availability needs review.
Research questions to consider
As you read Exablate Model 4000, Type 1.0 & Type 1.1 - Information for Prescribers, ask which audience the creator addresses, what problem or idea organises the work, what evidence is presented, and which assumptions remain unstated. Note whether important terms are defined consistently and whether examples represent a broader pattern or a narrow case. For quantitative material, record units, time periods, formulas and data sources. For interpretive material, separate the creator's language from your own summary.
A second set of questions concerns relevance today. Which parts remain durable, which depend on their historical or institutional setting, and what would need confirmation from a newer source? Following the tags and the Medicine & Wellbeing collection can reveal useful comparisons. Agreement between sources can strengthen confidence, while disagreement can point to changing definitions, methods, evidence or priorities.
Finally, decide what you need from the item: background knowledge, a quotation, a worked example, a model, a visual explanation or a starting bibliography. That purpose should guide the depth of reading and the notes you keep. Doxxly helps locate and navigate the source; careful interpretation remains the reader's responsibility.